Comprehensive Insight Generation for Product Development

Target RWE generates complete, longitudinal datasets with the power of advanced analytics and rigorous causal inference methodologies to uncover deep insights on unmet needs, disease progression, and the efficacy and safety of new treatments in the real world.

Schedule a Meeting

A Partner for Your Clinical Programs

With strong expertise in liver disease, gastroenterology, and dermatology, Target RWE’s multi-stakeholder model allows you to develop robust disease protocols to inform study objectives and endpoints. Our registries contain all relevant disease state variables, which when combined with our digital collection of patient and clinician reported outcomes and biosamples provide a framework for decisions on study entry criteria and site selection – reducing unnecessary procedures and costly protocol amendments.

Healthcare Research & Development Abstract Stock Photo

Demonstrate Valuable Insights with
Real-World Evidence

Target RWE’s cross-sectional and longitudinally complete registries encompass diverse patient populations beyond those traditionally captured in Phase 2 and 3 trials, generating more meaningful evidence on product effectiveness and safety in the real world. We provide insights on natural history of disease, treatment patterns, disease progression and other clinical questions. Execute your publication strategy with confidence and speed by joining our unique collaborative academic model, which taps not just into our patient registries but our network of leading clinical investigators.

Phases of Drug Development Stock Photo

Comprehensive Treatment Comparisons for Informed Decision Making

Leverage our proven advanced analytics and diverse real-world data to evaluate comparative effectiveness, safety, and cost-effectiveness of new therapies. Target RWE’s patient-centered analyses utilize patient-reported outcome (PRO) and clinician-reported outcome (ClinRO) measures to inform disease burden, empowering you with the insights necessary to improve healthcare utilization.

HEOR Abstract Visual Stock

Real-World Data for Regulatory Compliance & Safety

Target RWE’s fit-for-purpose longitudinal registries, ability to incorporate clinician-reported outcomes, and validated analytics software provide comprehensive solutions to meet FDA and pharmacovigilance risk assessment committee requests for new drug applications. Our research collaboration agreement with the FDA, combined with proven experience in meeting post marketing commitments and managing adjudication committees, enable us to be your trusted partner for regulatory decision-making.

Regulatory and Pharmacovigilance Stock

Patient Insights for Strategic Product Positioning

Target RWE's detailed patient journeys identify meaningful data points in disease that can inform your product positioning and marketing plan. Our large datasets, combined with novel analytical and causal inference methodology identify patient phenotypes with high unmet need, predict disease progression, and support identification of patients who will benefit most from your new therapy.

 

Commercial Analytics Stock

Fit-for-Purpose Registries for Advanced Research

Target RWE collaborates with a renowned network of clinical investigators to enroll large patient cohorts, capturing up to 5 years of retrospective and 15 years of prospective follow-up – creating some of the largest and most comprehensive real-world patient registries in the U.S.

0+
Academic & Community Sites
0+
Therapeutic Areas
0+
Disease Indications
0+
Patients with Biosamples
0+
Liver Disease Patients
0+
Publications

New Publications

title

Dermatology

Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry.

title

Dermatology

Correlation between achieving SALT 20 score and clinician- and patient-reported outcomes among patients diagnosed with alopecia areata in the US: An assessment from the TARGET-DERM AA registry.

title

Hepatocellular Carcinoma (HCC)

DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy

title

Pharmacoepidemiology

Advancing Principled Pharmacoepidemiologic Research to Support Regulatory and Healthcare Decision Making: The Era of Real-World Evidence

title

Human Immunodeficiency Virus (HIV)

Use of tenofovir-based PrEP among pregnant women in South Africa

title

Dermatology

Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry.

In the News

Mar 07 2025

Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology Studies

Feb 20 2025

Causal Inference for Regulatory-Grade Evidence Generation: Behind the Data

Jan 31 2025

Maximizing the Value of Real-World Data: The Critical Role of Causal Inference in Pharmaceutical Innovation

Jan 07 2025

Highlander Health Announces Inaugural Investment of Target RWE

Contact

Have a Question or Want to Learn More?

Fill in your contact information & a member from our team will be in contact.

By Submitting this form, you consent to your information used by Target RWE for the purpose of contacting you to better understand your potential interest in Target RWE and/or its services. For more information, see our privacy policy.